TY - JOUR
T1 - Treatment of male osteoporosis
T2 - Recent advances with alendronate
AU - Ringe, J. D.
AU - Orwoll, E.
AU - Daifotis, A.
AU - Lombardi, A.
PY - 2002
Y1 - 2002
N2 - Overall, the data from the two alendronate studies clearly document the efficacy and safety of alendronate in osteoporotic men. The positive effects of alendronate on BMD, markers and fractures are very consistent between studies. Importantly, they are also very consistent with the results of multiple clinical studies conducted in postmenopausal women with osteoporosis. Treatment with 10 mg alendronate for 2 years produced significant and clinically meaningful increases in BMD, similar to those previously observed in postmenopausal women. Data from studies including men and women confirm the similarity of response suggested by singlegender studies. Consistent with much larger studies in postmenopausal women, alendronate 10 mg/day also reduced the incidence of new vertebral fracture and, correspondingly, reduced height loss. The safety and tolerability of alendronate in men was favorable and consistent with the safety profile previously observed in postmenopausal women. Alendronate represents an important and needed therapeutic advancement in the management of osteoporosis in men.
AB - Overall, the data from the two alendronate studies clearly document the efficacy and safety of alendronate in osteoporotic men. The positive effects of alendronate on BMD, markers and fractures are very consistent between studies. Importantly, they are also very consistent with the results of multiple clinical studies conducted in postmenopausal women with osteoporosis. Treatment with 10 mg alendronate for 2 years produced significant and clinically meaningful increases in BMD, similar to those previously observed in postmenopausal women. Data from studies including men and women confirm the similarity of response suggested by singlegender studies. Consistent with much larger studies in postmenopausal women, alendronate 10 mg/day also reduced the incidence of new vertebral fracture and, correspondingly, reduced height loss. The safety and tolerability of alendronate in men was favorable and consistent with the safety profile previously observed in postmenopausal women. Alendronate represents an important and needed therapeutic advancement in the management of osteoporosis in men.
UR - http://www.scopus.com/inward/record.url?scp=0036117810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036117810&partnerID=8YFLogxK
U2 - 10.1007/s001980200013
DO - 10.1007/s001980200013
M3 - Review article
C2 - 11991437
AN - SCOPUS:0036117810
SN - 0937-941X
VL - 13
SP - 195
EP - 199
JO - Osteoporosis International
JF - Osteoporosis International
IS - 3
ER -